ISRCTN63321797已完成2 期
Immune response in the sentinel node in melanoma patients after the pre-operative administration of immune modulators GM-CSF and / or CpG 7909
VU University Medical Center0 个研究点目标入组 52 人开始时间: 2016年7月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Patients with histologically proven primary melanoma, who are eligible for a SLN biopsy.
排除标准
- •1. Treated with chemotherapy or immunotherapy in the last ten years
- •2. Autoimmune diseases
- •3. Congenital or acquired immunodeficiency
- •4. Use of immunosuppressive medications
研究者
相似试验
进行中（未招募）
1 期
Treatment of skin cancer using a different approach than surgery using an electroporation device that makes the tumour absorb more drug while leaving the healthy tissue alone combined with an immune modulator that enhances the anti-tumour immune response.Advanced Melanoma CancerEUCTR2014-004420-22-IEniversity College Cork10
进行中（未招募）
1 期
Immunization of disease-free melanoma patients with different HLA-A2 peptides.We want to vaccine HLA-A2 patients who had a cutaneous melanoma at the following AJCC stage T3b-T4 N0 M0, Tx N1-3 M0, Tx Nx M0. Disease-free after surgery. With no previous immunizations with the same peptides is allowed if a CTL response was observed. And the patients must be met all the inclusion criteria.EUCTR2006-000228-14-BECliniques Universitaires Saint-Luc28
已完成
不适用
Integrated analyses of melanoma-T cell interactions; relevance for immunotherapy100276651004090010035023skin cancerNL-OMON29970KI-AV40
已完成
1 期
Inducing Systemic Immunity and Regressions in Metastatic MelanomaMetastatic Malignant MelanomaNCT02350972NYU Langone Health88
Unknown
2 期
Vaccine Therapy in Treating Patients With Malignant MelanomaMelanoma (Skin)NCT00128583CancerVax Corporation